WO2004098652A1 - Radiolabelled thyroid stimulating hormone (tsh) and use thereof for the diagnosis and therapy of the differentiated thyroid tumors - Google Patents

Radiolabelled thyroid stimulating hormone (tsh) and use thereof for the diagnosis and therapy of the differentiated thyroid tumors Download PDF

Info

Publication number
WO2004098652A1
WO2004098652A1 PCT/IT2004/000234 IT2004000234W WO2004098652A1 WO 2004098652 A1 WO2004098652 A1 WO 2004098652A1 IT 2004000234 W IT2004000234 W IT 2004000234W WO 2004098652 A1 WO2004098652 A1 WO 2004098652A1
Authority
WO
WIPO (PCT)
Prior art keywords
tsh
thyroid
diagnosis
therapy
tumors
Prior art date
Application number
PCT/IT2004/000234
Other languages
English (en)
French (fr)
Inventor
Alberto Signore
Marco Chianelli
Original Assignee
Universita' Degli Studi Di Roma La Sapienza
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universita' Degli Studi Di Roma La Sapienza filed Critical Universita' Degli Studi Di Roma La Sapienza
Publication of WO2004098652A1 publication Critical patent/WO2004098652A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • radiolabelled recombinant TSH retains the ability to bind its own receptor and accordingly it can be advantageously employed as scintigraphic tracer and as radiomedicament, respectively in the diagnosis and therapy of differentiated thyroid tumors and related metastases, bypassing disadvantages of currently available techniques in this field.
  • radiolabelled TSH intravenously injected, allows the imaging by scintigraphy with ⁇ room of the tumor and normal thyroid tissue, consequently to tissue build-up of the thyroid-stimulating hormone due to the binding with the receptor thereof.
  • the authors have developed a protocol for efficient preparation of the scintigraphic tracer according to the invention, which allows to maintain an elevated specific activity and stability of the protein even subsequently to the delicate labelling process with 99m TC.
  • the same labelling method can be used, with slight changes, for the proteinlabelling with Rhenium radioisotopes ( 186 Re and 188 Re) that, even emitting beta-type radiations, have chemical characteristic similar to those of 99m Tc.
  • the recombinant human TSH is already employed in humans in a non-radioactive form and its systemic administration is safe and does not produce side effects.
  • the labelling has been performed through enzymatic method (Burrin JM; Comparison between human 125 l-labelled TSH labelled with lactoperoxidase or chloramine-T advantages in the use of enzymically labelled antigen in a RIA for human TSH. Clinica Chimica Acta 1976; 70:153-159), because comparative studies of several iodination methods (Kermode JC, Thompson BD; lodination of TSH for receptor-binding studies with human thyroid membranes: effects of specific activity and method of iodination. J Endocr 1980; 84:439-447) have shown that the protein does not suffer damages, maintaining affinity for its receptor.
  • TPC-1 deriving from the papillary carcinoma of the thyroid, which expresses the receptor for TSH
  • ARO deriving from the anaplastic carcinoma of the thyroid, that does not express the TSH receptor.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PCT/IT2004/000234 2003-05-05 2004-04-27 Radiolabelled thyroid stimulating hormone (tsh) and use thereof for the diagnosis and therapy of the differentiated thyroid tumors WO2004098652A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITRM2003A000214 2003-05-05
IT000214A ITRM20030214A1 (it) 2003-05-05 2003-05-05 Ormone stimolante la tiroide (tsh) radiomarcato e suo uso

Publications (1)

Publication Number Publication Date
WO2004098652A1 true WO2004098652A1 (en) 2004-11-18

Family

ID=29765796

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IT2004/000234 WO2004098652A1 (en) 2003-05-05 2004-04-27 Radiolabelled thyroid stimulating hormone (tsh) and use thereof for the diagnosis and therapy of the differentiated thyroid tumors

Country Status (2)

Country Link
IT (1) ITRM20030214A1 (it)
WO (1) WO2004098652A1 (it)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022023419A1 (fr) * 2020-07-30 2022-02-03 Assistance Publique Des Hopitaux De Paris Procede et dispositif de traitement d'images en scintigraphie thyroïdienne

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990008528A1 (en) * 1989-01-11 1990-08-09 The United States Of America, Represented By The Secretary, United States Department Of Commerce Biologically active synthetic thyrotropin and cloned gene for producing same
WO1994009814A1 (en) * 1992-11-05 1994-05-11 B.R.A.H.M.S Diagnostica Gmbh Purified tsh preparation, process for its production and its use for the production of tsh tracers for tsh receptor assays and in tsh receptor assays
WO1999040116A1 (en) * 1998-02-03 1999-08-12 The University Of Melbourne Process for expression of thyroid stimulating hormone receptor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990008528A1 (en) * 1989-01-11 1990-08-09 The United States Of America, Represented By The Secretary, United States Department Of Commerce Biologically active synthetic thyrotropin and cloned gene for producing same
WO1994009814A1 (en) * 1992-11-05 1994-05-11 B.R.A.H.M.S Diagnostica Gmbh Purified tsh preparation, process for its production and its use for the production of tsh tracers for tsh receptor assays and in tsh receptor assays
WO1999040116A1 (en) * 1998-02-03 1999-08-12 The University Of Melbourne Process for expression of thyroid stimulating hormone receptor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CORSETTI F ET AL: "Radioiodinated Recombinant Human TSH: A Novel Radiopharmaceutical for Thyroid Cancer Metastases Detection", CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS 2004 UNITED STATES, vol. 19, no. 1, 2004, pages 57 - 63, XP009035972, ISSN: 1084-9785 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022023419A1 (fr) * 2020-07-30 2022-02-03 Assistance Publique Des Hopitaux De Paris Procede et dispositif de traitement d'images en scintigraphie thyroïdienne
FR3113163A1 (fr) * 2020-07-30 2022-02-04 Assistance Publique Des Hopitaux De Paris Procede et dispositif de traitement d’images en scintigraphie thyroïdienne

Also Published As

Publication number Publication date
ITRM20030214A1 (it) 2004-11-06
ITRM20030214A0 (it) 2003-05-05

Similar Documents

Publication Publication Date Title
JP3853354B2 (ja) 放射性標識ペプチドおよびタンパク質の自己放射線分解を防止する安定剤
Decristoforo et al. 99m Tc-EDDA/HYNIC-TOC: a new 99m Tc-labelled radiopharmaceutical for imaging somatostatin receptor-positive tumours: first clinical results and intra-patient comparison with 111 In-labelled octreotide derivatives
Bangard et al. Detection of somatostatin receptor-positive tumours using the new 99m Tc-tricine-HYNIC-D-Phe 1-Tyr 3-octreotide: first results in patients and comparison with 111 In-DTPA-D-Phe 1-octreotide
Zamora et al. Experimental radiotherapy of receptor‐positive human prostate adenocarcinoma with 188Re‐RC‐160, a directly‐radiolabeled somatostatin analogue
JP3918157B2 (ja) ソマトスタチン結合性ペプチド−金属キレートコンジュゲート
Blower et al. Pentavalent rhenium-188 dimercaptosuccinic acid for targeted radiotherapy: synthesis and preliminary animal and human studies
Hoffend et al. Gallium-68-DOTA-albumin as a PET blood-pool marker: experimental evaluation in vivo
IL275317B (en) A complex containing a compound against psma attached to a radioactive nucleus of lead or thorium
US20110117012A1 (en) Radiolabeled gallium complexes, methods for synthesis and use for pet imaging of egfr expression in malignant tumors
Chakraborty et al. Tracer level radiochemistry to clinical dose preparation of 177Lu-labeled cyclic RGD peptide dimer
EP2795317B1 (en) Composition for use in a method for cancer selection
Pujatti et al. Radiolabeling of substance p with lutetium-177 and biodistribution study in rat pancreatic tumor xenografted nude mice
Orsini et al. Single-photon emitting radiopharmaceuticals for diagnostic applications
Jalilian et al. Preparation, quality control and biodistribution studies of two [111In]-rituximab immunoconjugates
WO2004098652A1 (en) Radiolabelled thyroid stimulating hormone (tsh) and use thereof for the diagnosis and therapy of the differentiated thyroid tumors
US6824759B2 (en) Radiolabeled vasoactive intestinal peptide analogs for imaging and therapy
Yu et al. Evaluation of 111In-DOTA-F56 peptide targeting VEGFR1 for potential non-invasive gastric cancer xenografted tumor mice Micro-SPECT imaging
Lin et al. Biological Evaluation of [18F] AlF-NOTA-NSC-GLU as a Positron Emission Tomography Tracer for Hepatocellular Carcinoma
Jalilian et al. Preparation, quality control and biodistribution studies of [67Ga]-DOTA-anti-CD20
ES2307325T3 (es) Metodo para aumentar la acumulacion en tejidos de compuestos raiomarcados.
WO2004071505A2 (en) Radiolabelled d-amino acids for use in diagnosis with spect and pet and systemic radionuclide therapy
Kim et al. Comparison of the PSMA target efficiency and in vivo biodistribution among [68Ga] ludotadipep,[18F] DCFPyL, and [68Ga] PSMA-11 in a tumor xenograft model
Jalilian et al. Preparation and quality control of radiometal-DOTA-Rituximab
Orsini et al. Single-Photon-Emitting Radiopharmaceuticals
Arnberg et al. Distribution and elimination of the somatostatin analogue (111In-DTPA-D-Phe1)-octreotide (OctreoScan111)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
122 Ep: pct application non-entry in european phase